NICE has implemented new measures to evaluate the cost-effectiveness of medicines, following a policy change that aims to ...

Learn how the MHRA and NICE are getting medicines to patients 3 to 6 months sooner by delivering same time decisions on ...

People who have had a heart attack, stroke, or serious circulation problem in their legs, and who also carry excess weight, can now be offered a weekly injection to help protect them from a further ...

Public Health Minister Sharon Hodgson said: "Every woman with endometriosis deserves fertility care that recognises the complexity of her condition. This landmark guidance will ensure women can access ...

Sophie Cooper, Senior Scientific Adviser, explains the importance of the recently published EQ-5D-5L value set and how it has ...

Adults with a first episode of psychosis start treatment in early intervention in psychosis services within 2 weeks of referral. Early intervention in psychosis services can improve clinical outcomes, ...

Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity [ID6441] ...

Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards ...

Ruxolitinib cream for treating non-segmental vitiligo in people 12 years and over TA1140 17 March 2026 17 March 2026 ...

There is a commercial access agreement for dupilumab. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact GB-PatientAccess@sanofi.com ...

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy Technology appraisal guidance TA673 Published: 17 ...

Evidence-based recommendations on pembrolizumab (Keytruda) for treating PD-L1-positive non-small-cell lung cancer in adults who have had chemotherapy. In September 2017, this guidance was amended ...